CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF517 (ImmuneEditome ID:340385)

1. Gene summary of enriched editing regions for ZNF517

check button Gene summary
Gene informationGene symbol

ZNF517

Gene ID

340385

GeneSynonyms-
GeneCytomap

8q24.3

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 517
GeneModificationdate20230517
UniprotIDQ6ZMY9;G3V191;E9PIL1
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr8:144808993-144809981:+ENST00000526178.1ENSG00000197363.8ZNF517ncRNA_intronicAluJb,AluJr,(TCTA)n,MLT2B3,AluSx1chr8:144808993-144809981:+.alignment


Top

2. Tumor-specific enriched editing regions for ZNF517


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000197363.8,ZNF517KICHEAG5.1632e-04image
chr8:144808993-144809981:+LUADEER1.2325e-02image
ENSG00000197363.8,ZNF517LUADEAG1.2180e-02image
chr8:144808993-144809981:+THCAEER2.9397e-05image
ENSG00000197363.8,ZNF517THCAEAG2.6981e-05image
ENSG00000197363.8,ZNF517UCECEAG1.3922e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr8:144808993-144809981:+THCAPathEER1.3878e-041.3517e-030.1444image
ENSG00000197363.8,ZNF517THCAPathEAG2.1539e-041.8616e-030.1401image
ENSG00000197363.8,ZNF517UCSCliEAG1.5043e-024.0599e-03-0.4115image
chr8:144808993-144809981:+UCSCliEER1.3889e-023.7584e-03-0.4146image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for ZNF517


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr8:144808993-144809981:+BLCAEERENSG00000197363,ZNF517-0.38088.3257e-098.4886e-13-0.4050imageNBUD13;CSTF2T;DDX3X;DDX54;DHX9;EIF4A3;ELAVL1;FBL;FUS;GTF2F1;HNRNPM;IGF2BP3;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SRSF1;U2AF2;UPF1;YWHAGNAT_cells_CD4_memory_activatedGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB
chr8:144808993-144809981:+LIHCEERENSG00000197363,ZNF517-0.44524.8547e-113.5316e-15-0.4494imageNBUD13;CSTF2T;DDX3X;DDX54;DHX9;EIF4A3;ELAVL1;FBL;FUS;GTF2F1;HNRNPM;IGF2BP3;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SRSF1;U2AF2;UPF1;YWHAGNAMacrophages_M0GSVA_HALLMARK_HYPOXIA
chr8:144808993-144809981:+GBMEERENSG00000238000,RP11-274E7.20.35072.0927e-033.2469e-070.4027imageNNNAMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr8:144808993-144809981:+GBMEERENSG00000204261,PSMB8-AS10.29021.5797e-023.8542e-070.4003imageNEIF4A3;FUS;SRSF1;U2AF2;UPF1;YTHDF1NAMacrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr8:144808993-144809981:+THCAEERENSG00000124160,NCOA5-0.43388.5213e-214.1746e-25-0.4438imageNBCCIP;BUD13;CSTF2T;DDX3X;DDX42;DDX54;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPM;IGF2BP3;LARP7;LIN28;LIN28B;MOV10;MSI2;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SND1;SRSF1;SRSF10;TRA2A;U2AF2;UPF1;YTHDC1;YTHDF1;YTHDF2;YWHAGNADendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr8:144808993-144809981:+OVEERENSG00000197363,ZNF517-0.46242.5722e-091.1125e-11-0.4327imageNBUD13;CSTF2T;DDX3X;DDX54;DHX9;EIF4A3;ELAVL1;FBL;FUS;GTF2F1;HNRNPM;IGF2BP3;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SRSF1;U2AF2;UPF1;YWHAGNAT_cells_follicular_helperGSVA_HALLMARK_PANCREAS_BETA_CELLS
chr8:144808993-144809981:+OVEERENSG00000265660,MIR4664-0.46062.5915e-091.7882e-10-0.4088imageNNNANK_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr8:144808993-144809981:+OVEERENSG00000177954,RPS270.42391.1306e-079.8404e-110.4141imageNAUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPM;IGF2BP3;LARP7;LIN28;LIN28B;MOV10;MSI2;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SND1;SRSF1;TNRC6A;TRA2A;U2AF2;UPF1;YWHAGNAB_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr8:144808993-144809981:+OVEERENSG00000143256,PFDN20.42341.4901e-078.1896e-110.4157imageNAUH;BUD13;CPSF6;CSTF2T;DDX3X;DDX54;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;FXR2;GNL3;GTF2F1;IGF2BP3;LIN28;LIN28B;MOV10;MSI2;NOP58;PRPF8;RBFOX2;SND1;SRSF1;SRSF10;TRA2A;U2AF2;UPF1;YTHDC1;YWHAGNAB_cells_memoryGSVA_HALLMARK_HEDGEHOG_SIGNALING
chr8:144808993-144809981:+OVEERENSG00000148396,SEC16A-0.41233.1194e-071.5978e-10-0.4098imageNAUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPM;IGF2BP3;LARP7;LIN28;LIN28B;MOV10;MSI2;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SND1;SRSF1;SRSF10;TNRC6A;TRA2A;U2AF2;UPF1;YTHDC1;YTHDF1;YTHDF2;YWHAGNAT_cells_gamma_deltaGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

More results



Top

4. Enriched editing regions and immune related splicing for ZNF517


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr8:144808993-144809981:+
OVEERMEXENSG00000135451.8chr1249329856:49329991:49330144:49330180:49330893:49330943:49331213:49331407-0.43301.9756e-072.2076e-10-0.4103imageNAUH;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;GNL3;GTF2F1;HNRNPM;IGF2BP3;LIN28;LIN28B;MOV10;MSI2;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SND1;SRSF1;TNRC6A;TRA2A;U2AF2;UPF1;YTHDC1;YTHDF1;YWHAGTROAPMacrophages_M2GSVA_HALLMARK_HEDGEHOG_SIGNALING
chr8:144808993-144809981:+
OVEERMEXENSG00000135451.8chr1249329856:49329991:49330144:49330180:49330660:49330943:49331213:49331407-0.43291.9766e-072.2104e-10-0.4103imageNAUH;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FXR1;FXR2;GNL3;GTF2F1;HNRNPM;IGF2BP3;LIN28;LIN28B;MOV10;MSI2;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SND1;SRSF1;TNRC6A;TRA2A;U2AF2;UPF1;YTHDC1;YTHDF1;YWHAGTROAPMacrophages_M2GSVA_HALLMARK_HEDGEHOG_SIGNALING
chr8:144808993-144809981:+
OVEERMEXENSG00000108821.9chr1750188902:50189010:50189167:50189275:50195231:50195330:50195433:501954780.39375.2159e-062.5004e-100.4058imageNCSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;FXR1;FXR2;HNRNPM;IGF2BP3;LIN28;LIN28B;MOV10;NOP58;PRPF8;RBFOX2;SND1;SRSF1;U2AF2;UPF1;YTHDC1;YTHDF1COL1A1Macrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr8:144808993-144809981:+
OVEERMEXENSG00000022840.11chr12120557545:120557682:120560725:120560886:120571190:120571291:120575630:120575688-0.42784.1188e-071.1547e-10-0.4127imageNAUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPM;IGF2BP3;LARP7;LIN28;LIN28B;MOV10;MSI2;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SND1;SRSF1;SRSF10;TNRC6A;TRA2A;U2AF2;UPF1;YTHDC1;YTHDF1;YWHAGNAB_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr8:144808993-144809981:+
OVEERA3ENSG00000151148.9chr12109489918:109490004:109491044:109491127:109490489:109491127-0.26175.2390e-038.4141e-11-0.4316imageNAUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DHX9;EIF4A3;ELAVL1;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPM;IGF2BP3;LARP7;LIN28;LIN28B;MOV10;MSI2;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SND1;SRSF1;SRSF10;TNRC6A;TRA2A;U2AF2;UPF1;YTHDC1;YTHDF1;YTHDF2;YWHAGNAT_cells_gamma_deltaGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr8:144808993-144809981:+
OVEERMEXENSG00000104131.8chr1544550875:44550930:44551430:44551522:44554550:44554667:44557488:445576500.42007.4697e-075.4659e-110.4192imageNAUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPM;IGF2BP3;LARP7;LIN28;LIN28B;MOV10;MSI2;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SND1;SRSF1;SRSF10;TNRC6A;TRA2A;U2AF2;UPF1;YTHDC1;YTHDF1;YWHAGNAB_cells_memoryGSVA_HALLMARK_MITOTIC_SPINDLE
chr8:144808993-144809981:+
OVEERIRENSG00000151148.9chr12109489918:109490004:109491044:1094911270.21023.5270e-023.1172e-090.4142imageNAUH;BCCIP;BUD13;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DHX9;EIF4A3;ELAVL1;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPM;IGF2BP3;LARP7;LIN28;LIN28B;MOV10;MSI2;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SND1;SRSF1;SRSF10;TNRC6A;TRA2A;U2AF2;UPF1;YTHDC1;YTHDF1;YTHDF2;YWHAGNAB_cells_memoryGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr8:144808993-144809981:+
OVEERMEXENSG00000115486.7chr285553231:85553497:85554142:85554306:85558916:85559075:85560814:85560985-0.36983.3408e-055.8961e-11-0.4186imageNAUH;BCCIP;BUD13;CSTF2T;DDX3X;DDX42;DDX54;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPM;IGF2BP3;LARP7;LIN28;LIN28B;MOV10;MSI2;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SND1;SRSF1;TNRC6A;TRA2A;U2AF2;UPF1;YTHDC1;YTHDF1GGCXNK_cells_activatedGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr8:144808993-144809981:+
OVEERMEXENSG00000108821.9chr1750187014:50187122:50187483:50187537:50196154:50196199:50196313:501963670.36135.0782e-054.6055e-100.4002imageNCSTF2T;DDX54;EIF4A3;ELAVL1;FBL;FMR1;FUS;FXR1;FXR2;HNRNPM;IGF2BP3;LIN28;LIN28B;MOV10;NOP58;PRPF8;RBFOX2;SND1;SRSF1;U2AF2;UPF1;YTHDC1;YTHDF1COL1A1B_cells_memoryGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr8:144808993-144809981:+
OVEERIRENSG00000115486.7chr285558439:85558605:85558916:855590750.41221.4318e-067.0925e-120.4372imageNAUH;BCCIP;BUD13;CSTF2T;DDX3X;DDX42;DDX54;DHX9;EIF4A3;EIF4G2;ELAVL1;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPM;IGF2BP3;LARP7;LIN28;LIN28B;MOV10;MSI2;NOP58;NUMA1;PRPF8;RBFOX2;SLTM;SND1;SRSF1;TNRC6A;TRA2A;U2AF2;UPF1;YTHDC1;YTHDF1GGCXMacrophages_M2GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

More results



Top

5. Enriched editing regions and immune infiltration for ZNF517


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr8:144808993-144809981:+BLCAEERMacrophages_M18.2914e-040.1959image
ENSG00000197363.8,ZNF517BLCAEAGMacrophages_M19.7562e-040.1933image
chr8:144808993-144809981:+BRCAEERNK_cells_activated1.4972e-040.1186image
ENSG00000197363.8,ZNF517BRCAEAGNK_cells_activated3.2706e-040.1124image
chr8:144808993-144809981:+CESCEERMonocytes1.0274e-030.2260image
ENSG00000197363.8,ZNF517CESCEAGMonocytes7.3080e-040.2324image
chr8:144808993-144809981:+CHOLEERT_cells_CD4_memory_activated6.6640e-030.4845image
ENSG00000197363.8,ZNF517CHOLEAGT_cells_CD4_memory_activated4.9075e-030.4999image
ENSG00000197363.8,ZNF517COADEAGT_cells_gamma_delta4.5461e-040.2819image
ENSG00000197363.8,ZNF517DLBCEAGB_cells_memory7.4770e-030.5539image
chr8:144808993-144809981:+GBMEERT_cells_CD4_memory_resting2.8336e-020.1791image
ENSG00000197363.8,ZNF517GBMEAGT_cells_CD4_memory_resting4.2660e-020.1658image
ENSG00000197363.8,ZNF517HNSCEAGMacrophages_M22.3733e-020.1405image
chr8:144808993-144809981:+KIRCEERT_cells_gamma_delta1.3121e-030.1832image
ENSG00000197363.8,ZNF517KIRCEAGT_cells_gamma_delta1.1386e-030.1849image
ENSG00000197363.8,ZNF517KIRPEAGT_cells_CD4_memory_activated2.2496e-060.3060image
chr8:144808993-144809981:+LGGEERB_cells_naive5.7700e-040.1503image
ENSG00000197363.8,ZNF517LGGEAGB_cells_naive2.9164e-040.1581image
chr8:144808993-144809981:+LIHCEERMacrophages_M01.6910e-03-0.1878image
ENSG00000197363.8,ZNF517LIHCEAGMacrophages_M01.7895e-03-0.1865image
chr8:144808993-144809981:+LUADEERT_cells_CD4_memory_activated4.4515e-030.1436image
ENSG00000197363.8,ZNF517LUADEAGT_cells_CD4_memory_activated4.5772e-030.1431image
chr8:144808993-144809981:+LUSCEERT_cells_CD4_memory_activated5.7659e-040.1818image
ENSG00000197363.8,ZNF517LUSCEAGT_cells_CD4_memory_activated5.0782e-040.1833image
ENSG00000197363.8,ZNF517MESOEAGMonocytes2.4730e-02-0.2874image
chr8:144808993-144809981:+OVEERB_cells_memory1.3122e-020.1652image
ENSG00000197363.8,ZNF517OVEAGB_cells_memory9.2699e-030.1720image
chr8:144808993-144809981:+PCPGEERT_cells_CD4_memory_resting6.3509e-03-0.2110image
ENSG00000197363.8,ZNF517PCPGEAGT_cells_CD4_memory_resting7.7079e-03-0.2061image
ENSG00000197363.8,ZNF517PRADEAGT_cells_CD4_naive7.5081e-030.1279image
ENSG00000197363.8,ZNF517READEAGEosinophils1.6777e-020.2935image
chr8:144808993-144809981:+SARCEERMacrophages_M12.1666e-040.2562image
ENSG00000197363.8,ZNF517SARCEAGMacrophages_M11.1770e-040.2651image
chr8:144808993-144809981:+SKCMEERT_cells_CD4_memory_activated8.2093e-040.1707image
ENSG00000197363.8,ZNF517SKCMEAGT_cells_CD4_memory_activated1.1319e-030.1662image
chr8:144808993-144809981:+STADEERMonocytes2.7773e-03-0.2217image
ENSG00000197363.8,ZNF517STADEAGMonocytes2.5909e-03-0.2197image
ENSG00000197363.8,ZNF517TGCTEAGMacrophages_M24.4803e-08-0.4437image
chr8:144808993-144809981:+THCAEERT_cells_CD4_memory_activated2.1185e-030.1384image
ENSG00000197363.8,ZNF517THCAEAGT_cells_CD4_memory_activated1.9921e-030.1390image
ENSG00000197363.8,ZNF517THYMEAGT_cells_CD4_memory_activated8.1402e-050.3651image
ENSG00000197363.8,ZNF517UCECEAGMacrophages_M12.7607e-020.1823image
chr8:144808993-144809981:+UCSEERT_cells_regulatory_(Tregs)3.4273e-020.3095image
ENSG00000197363.8,ZNF517UCSEAGT_cells_regulatory_(Tregs)3.4723e-020.3088image


Top

6. Enriched editing regions and immune gene sets for ZNF517


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr8:144808993-144809981:+BLCAEER4.7422e-02image4.0685e-050.2393image
ENSG00000197363.8,ZNF517BLCAEAG4.5693e-02image4.6992e-050.2374image
ENSG00000197363.8,ZNF517HNSCEAG8.2906e-03image1.4574e-030.1968image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000197363.8,ZNF517ACCGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG2.0630e-02-0.3008image
chr8:144808993-144809981:+BLCAGSVA_HALLMARK_COAGULATIONEER6.7223e-060.2618image
ENSG00000197363.8,ZNF517BLCAGSVA_HALLMARK_COAGULATIONEAG7.2310e-060.2609image
ENSG00000197363.8,ZNF517BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.3264e-120.2148image
chr8:144808993-144809981:+BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.2182e-110.2104image
ENSG00000197363.8,ZNF517CESCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.6895e-030.2164image
chr8:144808993-144809981:+CESCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.7382e-030.2159image
chr8:144808993-144809981:+CHOLGSVA_HALLMARK_COAGULATIONEER4.9784e-02-0.3613image
ENSG00000197363.8,ZNF517COADGSVA_HALLMARK_HYPOXIAEAG3.3364e-040.2881image
ENSG00000197363.8,ZNF517DLBCGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG1.7566e-030.6279image
ENSG00000197363.8,ZNF517ESCAGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.3733e-02-0.2437image
chr8:144808993-144809981:+ESCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER3.9192e-02-0.2241image
chr8:144808993-144809981:+GBMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.7927e-03-0.2529image
ENSG00000197363.8,ZNF517GBMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.4236e-03-0.2582image
ENSG00000197363.8,ZNF517HNSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.7399e-070.3178image
chr8:144808993-144809981:+KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER7.0713e-050.2255image
ENSG00000197363.8,ZNF517KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG6.6580e-050.2256image
ENSG00000197363.8,ZNF517KIRPGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG4.8292e-060.2963image
ENSG00000197363.8,ZNF517LGGGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG3.8167e-140.3234image
chr8:144808993-144809981:+LGGGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER2.2087e-140.3262image
ENSG00000197363.8,ZNF517LIHCGSVA_HALLMARK_HYPOXIAEAG1.1493e-020.1514image
chr8:144808993-144809981:+LIHCGSVA_HALLMARK_HYPOXIAEER8.8566e-030.1570image
ENSG00000197363.8,ZNF517LUADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.0489e-060.2335image
chr8:144808993-144809981:+LUADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER3.5013e-060.2321image
chr8:144808993-144809981:+LUSCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.1519e-060.2548image
ENSG00000197363.8,ZNF517LUSCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG8.9728e-070.2569image
ENSG00000197363.8,ZNF517MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG4.7385e-030.3570image
ENSG00000197363.8,ZNF517OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.4409e-09-0.3821image
chr8:144808993-144809981:+OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.0450e-10-0.4040image
ENSG00000197363.8,ZNF517PAADGSVA_HALLMARK_P53_PATHWAYEAG6.9491e-040.2884image
ENSG00000197363.8,ZNF517PCPGGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.8650e-040.2861image
chr8:144808993-144809981:+PCPGGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER9.2797e-050.2987image
ENSG00000197363.8,ZNF517PRADGSVA_HALLMARK_COAGULATIONEAG9.6747e-060.2101image
ENSG00000197363.8,ZNF517READGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG9.4066e-03-0.3174image
chr8:144808993-144809981:+SARCGSVA_HALLMARK_COMPLEMENTEER5.1231e-090.3948image
ENSG00000197363.8,ZNF517SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG8.7691e-090.3874image
ENSG00000197363.8,ZNF517SKCMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG7.2270e-070.2506image
chr8:144808993-144809981:+SKCMGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.0861e-060.2467image
chr8:144808993-144809981:+STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.1339e-020.1715image
ENSG00000197363.8,ZNF517STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG4.1729e-020.1495image
ENSG00000197363.8,ZNF517TGCTGSVA_HALLMARK_GLYCOLYSISEAG5.3381e-08-0.4414image
ENSG00000197363.8,ZNF517THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG3.3565e-060.2078image
chr8:144808993-144809981:+THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.1006e-060.2087image
ENSG00000197363.8,ZNF517THYMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG8.1690e-06-0.4093image
ENSG00000197363.8,ZNF517UCECGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.9985e-040.3031image


Top

7. Enriched editing regions and drugs for ZNF517


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000197363.8,ZNF517ACCBMS.708163EAG1.3578e-020.3197image
ENSG00000197363.8,ZNF517BLCACMKEAG2.8488e-04-0.2123image
chr8:144808993-144809981:+BLCACMKEER2.1815e-04-0.2162image
ENSG00000197363.8,ZNF517BRCABortezomibEAG2.0672e-07-0.1619image
chr8:144808993-144809981:+BRCAAZD6244EER1.7715e-07-0.1629image
chr8:144808993-144809981:+CESCAxitinibEER4.7082e-040.2404image
ENSG00000197363.8,ZNF517CESCAxitinibEAG3.8393e-040.2440image
ENSG00000197363.8,ZNF517COADBIRB.0796EAG1.6300e-040.3021image
ENSG00000197363.8,ZNF517DLBCABT.888EAG6.3149e-040.6709image
chr8:144808993-144809981:+ESCACI.1040EER1.4103e-02-0.2654image
ENSG00000197363.8,ZNF517ESCACI.1040EAG1.4455e-02-0.2629image
chr8:144808993-144809981:+GBMBosutinibEER8.0099e-030.2158image
ENSG00000197363.8,ZNF517GBMBosutinibEAG9.7458e-030.2104image
ENSG00000197363.8,ZNF517HNSCCI.1040EAG1.3677e-05-0.2666image
ENSG00000197363.8,ZNF517KICHFTI.277EAG4.6407e-02-0.3019image
ENSG00000197363.8,ZNF517KIRCCI.1040EAG5.5869e-04-0.1958image
chr8:144808993-144809981:+KIRCCI.1040EER6.0678e-04-0.1952image
ENSG00000197363.8,ZNF517KIRPBIBW2992EAG4.2512e-080.3516image
ENSG00000197363.8,ZNF517LGGBAY.61.3606EAG4.8943e-120.2966image
chr8:144808993-144809981:+LGGBAY.61.3606EER7.7061e-120.2939image
chr8:144808993-144809981:+LIHCDasatinibEER1.8316e-02-0.1509image
ENSG00000197363.8,ZNF517LIHCDasatinibEAG2.3605e-02-0.1446image
chr8:144808993-144809981:+LUADGemcitabineEER6.3437e-06-0.2261image
ENSG00000197363.8,ZNF517LUADGemcitabineEAG6.1658e-06-0.2264image
chr8:144808993-144809981:+LUSCBMS.536924EER1.4340e-05-0.2280image
ENSG00000197363.8,ZNF517LUSCBMS.536924EAG1.7381e-05-0.2256image
ENSG00000197363.8,ZNF517MESODasatinibEAG7.3248e-03-0.3401image
ENSG00000197363.8,ZNF517OVAZD6482EAG2.4053e-090.3830image
chr8:144808993-144809981:+OVAZD6482EER2.2141e-100.4077image
ENSG00000197363.8,ZNF517PAADAMG.706EAG2.7631e-030.2576image
chr8:144808993-144809981:+PCPGBAY.61.3606EER3.4424e-060.3514image
ENSG00000197363.8,ZNF517PCPGBAY.61.3606EAG4.2257e-060.3484image
ENSG00000197363.8,ZNF517PRADCI.1040EAG9.3244e-06-0.2105image
ENSG00000197363.8,ZNF517READBosutinibEAG1.2398e-020.3062image
chr8:144808993-144809981:+SARCBortezomibEER1.4509e-07-0.3581image
ENSG00000197363.8,ZNF517SARCBortezomibEAG3.1248e-06-0.3183image
chr8:144808993-144809981:+SKCMCCT018159EER5.9728e-06-0.2296image
ENSG00000197363.8,ZNF517SKCMCCT018159EAG4.4095e-06-0.2327image
chr8:144808993-144809981:+STADCI.1040EER1.1513e-05-0.3205image
ENSG00000197363.8,ZNF517STADCI.1040EAG4.8563e-05-0.2933image
ENSG00000197363.8,ZNF517TGCTFTI.277EAG4.6239e-080.4433image
ENSG00000197363.8,ZNF517THCACI.1040EAG1.7894e-09-0.2670image
chr8:144808993-144809981:+THCACI.1040EER2.4347e-10-0.2807image
ENSG00000197363.8,ZNF517THYMAZD6244EAG1.8243e-13-0.6269image
ENSG00000197363.8,ZNF517UCECCI.1040EAG5.3664e-05-0.3278image
chr8:144808993-144809981:+UCSAG.014699EER4.1184e-030.4109image
ENSG00000197363.8,ZNF517UCSAG.014699EAG4.6124e-030.4062image
ENSG00000197363.8,ZNF517UVMGSK269962AEAG2.1427e-02-0.2653image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType